Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study
| Autor: | Francesco Pallone, Emma Calabrese, R. Sostegni, Livia Biancone, Claudio Papi, Fabiana Castiglione, Enrico Colombo, E. Angelucci, Fernando Rizzello, Gianmichele Meucci, Anna Kohn, Carmelina Petruzziello, Mario Cottone, Alessandra Geremia, Ambrogio Orlando, Gabriele Riegler, L. Benazzato, F. Mocciaro |
|---|---|
| Přispěvatelé: | Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F, Biancone, L, Orlando, A, Kohn, A, Colombo, E, Sostegni, R, Angelucci, E, Rizzello, F, Castiglione, Fabiana, Benazzato, L, Papi, C, Meucci, G, Riegler, G, Petruzziello, C, Mocciaro, F, Geremia, A, Calabrese, E, Cottone, M, Pallone, F., Castiglione, F, Riegler, Gabriele |
| Rok vydání: | 2006 |
| Předmět: |
Male
cancer risk Gastroenterology anus cancer metronidazole Crohn Disease cancer diagnosis Neoplasms Monoclonal 80 and over cancer survival Child Aged 80 and over Settore MED/12 - Gastroenterologia Crohn's disease Gastrointestinal agent azathioprine nonhodgkin lymphoma skin cancer adult steroid Smoking article leukemia Age Factors Antibodies Monoclonal Middle Aged aged female medicine.anatomical_structure priority journal mesalazine carcinogenesis medicine.drug medicine.medical_specialty Adolescent Rectum mercaptopurine Antibodies breast cancer Breast cancer basal cell carcinoma Gastrointestinal Agents ciprofloxacin Internal medicine medicine cancer Humans human Tumor Necrosis Factor-alpha business.industry Inflammatory Bowel Disease disease association larynx cancer Cancer Odds ratio medicine.disease major clinical study Infliximab Surgery infliximab adolescent bile duct carcinoma child Crohn disease male spinal cord cancer Adult Aged Epidemiologic Methods Female Skin cancer business |
| Zdroj: | Gut. 55:228-233 |
| ISSN: | 0017-5749 |
| Popis: | BACKGROUND AND AIMS: The widespread use of anti-tumour necrosis factor alpha antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. METHODS: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (+/-5 years), site of CD, age at diagnosis (+/-5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. RESULTS: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95% confidence interval 0.46-3.84); p=0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p=0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40-70 years) v 45 (27-72); p=0.50). CONCLUSION: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|